Equities

Merck & Co Inc

0QAH:LSE

Merck & Co Inc

  • Price (USD)130.70
  • Today's Change-0.10 / -0.08%
  • Shares traded2.43k
  • 1 Year change14.95%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 19:14 BST.
More ▼

Profile data is unavailable for this security.

About the company

Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.

  • Revenue in USD (TTM)61.40bn
  • Net income in USD2.31bn
  • Incorporated1970
  • Employees72.00k
  • Location
    Merck & Co Inc126 East Lincoln AvenueRAHWAY 07065United StatesUSA
  • Phone+1 (908) 740-4000Fax+1 (908) 423-1987
  • Websitehttps://www.merck.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0QAH:LSE since
announced		Transaction
value
Caraway Therapeutics IncAnnounced21 Nov 202321 Nov 2023Announced27.29%610.00m
Data delayed at least 20 minutes, as of May 17 2024 19:14 BST.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.